Test Price
2,800 AED✅ Home Collection Available
CRELD1 Gene Sequencing for Atrioventricular Septal Defect & Heterotaxy Syndrome in UAE | 2,800 AED | DHA Licensed Lab
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 & ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Interpretation by a DHA-licensed Consultant Medical Geneticist, integrated with your treating physician’s plan.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The CRELD1 gene test utilizes Next-Generation Sequencing (NGS) to detect pathogenic variants causing autosomal dominant atrioventricular septal defect (AVSD) with heterotaxy syndrome. In the UAE, this test is clinically indicated for infants and children with congenital heart malformations, visceral situs anomalies, and for at-risk family members.
| Feature | Our CRELD1 NGS Test | Closest Alternative (Sanger Sequencing Panel) |
|---|---|---|
| Precision | Full coding region ±20 bp intronic flanks; CNV detection capable | Single exon hotspot coverage; no CNV detection |
| Method | Next-Generation Sequencing (NGS) with Sanger confirmation | Conventional Sanger only |
| Speed | 3–4 Weeks (with genetic counselling inclusive) | 4–6 Weeks without pre‑test counselling |
| Sample Options | Whole Blood, Extracted DNA, FTA Card | Whole Blood only |
| UAE Compliance | Federal Decree-Law No. 45 of 2021 (PDPL) & Federal Law No. 2 of 2019 | Varies by provider |
Physician Insight & Clinical Safety Protocols
"A definitive molecular diagnosis of AVSD with heterotaxy via CRELD1 sequencing is instrumental for personalized surgical planning and familial cascade screening. The test results must be integrated with echocardiographic findings and clinical assessment by a multidisciplinary team to guide critical care decisions."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Medication & Clinical Advisory
Do not discontinue prescribed cardiac medications (diuretics, digoxin, ACE inhibitors) without consulting the treating cardiologist. This genetic test does not replace emergency assessment. If the patient develops cyanosis, respiratory distress, or syncope, seek immediate medical care.
Exclusion Criteria & Emergency Red Flags
- Not indicated for asymptomatic adults without confirmed family history of CRELD1-associated disorder.
- This test is not a screening tool for isolated congenital heart defects without heterotaxy signs.
- If the patient exhibits acute hemodynamic instability, severe arrhythmia, or oxygen saturation <85% on room air, emergency department transfer takes priority over genetic testing.
- Prenatal samples (amniocytes/CVS) require prior genetic counselling appointment – contact the lab before collection.
- Home collection is not suitable for critically ill neonates; hospital phlebotomy with monitoring is recommended.
Patient FAQ & Clinical Guidance
1. What does a positive CRELD1 result mean for my child’s heart surgery?
A positive CRELD1 variant confirms the molecular basis of AVSD with heterotaxy, enabling surgeons to anticipate complex cardiac anatomy and tailor the surgical approach. It allows for familial cascade screening. The pediatric cardiologist will explain the specific variant and its implications for future pregnancies within the family.
2. How is the sample collected, and is home service available across the UAE?
We offer VIP mobile phlebotomy across all emirates (Dubai, Abu Dhabi, Sharjah, Northern Emirates) from 8 AM to 11 PM daily. A trained pediatric phlebotomist performs a minimal-volume blood draw, transported via strict cold-chain. Results are delivered confidentially via encrypted email within 3 to 4 weeks following mandatory pre-test genetic counselling.
3. Is this test covered by insurance, and how do I check eligibility?
Most UAE insurance plans with genomic testing benefits cover this test when ordered by a DHA-licensed specialist. Send your policy details via WhatsApp to +971 54 548 8731 for instant pre-authorization verification. Self-pay option is fixed at 2,800 AED.
UAE Regulatory & Data Privacy Adherence
Your genetic data is processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds DHA Facility License No. 1143 and adheres to ISO 15189 & ISO 9001:2015 quality standards. All genomic data is encrypted at rest and in transit, with access restricted to authorized clinical personnel only.
Clinical & Logistical Metadata
| Test Name | CRELD1 Gene Sequencing (AVSD & Heterotaxy Syndrome) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | Q21.2 (Atrioventricular septal defect), Q20.9 (Heterotaxy syndrome) |
| LOINC Code | 94476-3 (CRELD1 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians